Search results - ORA - Oxford University Research Archive

1 - 23 of 23

1

Journal article

Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group.

Neil, H, Betteridge, D, Broome, K, et al.
1999-01-01

2

Journal article

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.

Neil, H, Huxley, R, Hawkins, M, et al.
2003-09-01

3

Journal article

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.

Neil, H, Seagroatt, V, Betteridge, D, et al.
2004-12-01

4

Journal article

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.

Neil, H, Hawkins, M, Durrington, P, et al.
2005-04-01

5

Journal article

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Colhoun, H, Betteridge, D, Durrington, P, et al.
2004-01-01

6

Journal article

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).

Raikou, M, McGuire, A, Colhoun, H, et al.
2007-04-01

7

Journal article

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Colhoun, H, Betteridge, D, Durrington, P, et al.
2009-11-01

8

Journal article

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).

Hitman, G, Colhoun, H, Newman, C, et al.
2007-12-01

9

Journal article

All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study.

Neil, H, Cooper, J, Betteridge, D, et al.
2010-08-01

10

Journal article

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).

Neil, H, DeMicco, D, Luo, D, et al.
2006-11-01

11

Journal article

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.

Colhoun, H, Betteridge, D, Durrington, P, et al.
2011-09-01

12

Journal article

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).

Colhoun, H, Betteridge, D, Durrington, P, et al.
2005-12-01

13

Journal article

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

Soedamah-Muthu, S, Charlton-Menys, V, Bao, W, et al.
2011-11-01

14

Journal article

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).

Charlton-Menys, V, Betteridge, D, Colhoun, H, et al.
2009-02-01

15

Journal article

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.

Betteridge, D, Bhatnager, D, Bing, R, et al.
1992-05-01

16

Journal article

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).

Charlton-Menys, V, Betteridge, D, Colhoun, H, et al.
2009-03-01

17

Journal article

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.

Humphries, SE, Whittall, R, Hubbart, C, et al.
2006-12-01

18

Journal article

Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS)

Charlton-Menys, V, Betteridge, D, Colhoun, H, et al.
2009-03-01

19

Journal article

Status report of lipid-lowering trials in diabetes.

Betteridge, D, Colhoun, H, Armitage, J
2000-12-01

20

Journal article

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.

Colhoun, H, Thomason, M, Mackness, M, et al.
2002-03-01

21

Journal article

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.

Soedamah-Muthu, S, Colhoun, H, Thomason, M, et al.
2003-04-01

22

Journal article

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.

Thomason, M, Colhoun, H, Livingstone, S, et al.
2004-08-01

23

Journal article

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).

Newman, C, Szarek, M, Colhoun, H, et al.
2008-09-01

TO TOP